Compare Live Nation Entertainment, Inc. (LYV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Live Nation Entertainment, Inc. trades at $183.14 (market cap $42.71B), while State Street SPDR S&P Biotech ETF trades at $159.49. Which is the better fit depends on your goals.
| LYV | XBI | |
|---|---|---|
Market Cap | $42.71B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $186.59 | $164.28 |
52-Week Low | $125.61 | $86.92 |
Enterprise Value | $44.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation (LYV) trades at $185.71, up 0.58% with strong bullish technical signals from moving averages. The stock shows mixed fundamentals with a high P/E of 117.49 but beat Q2 2026 earnings expectations. Revenue growth remains robust at $25.2B in 2025, though net margins are thin at 0.51%. Recent insider sales and legal concerns create headwinds despite analyst optimism.
Outlook remains cautiously optimistic with 87% analyst buy ratings and a $209.54 price target suggesting 13% upside. Key risks include elevated valuation, debt levels, and regulatory scrutiny. The company's dominant live events position and strong demand provide growth catalysts, but execution on cost management will be critical for profitability improvement.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
